Enanta Pharmaceuticals Inc Total Assets
Enanta Pharmaceuticals Inc total assets. Based on the latest financial reports, Enanta Pharmaceuticals Inc (ENTA) holds total assets worth $296.87 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market cap of Enanta Pharmaceuticals Inc for the company's overall valuation and market capitalisation.
Total Assets of Enanta Pharmaceuticals Inc (2011–2025)
Total assets of Enanta Pharmaceuticals Inc from 2011 to 2025. This chart illustrates how Enanta Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. See Enanta Pharmaceuticals Inc stock price for real-time trading data and today's change.
Enanta Pharmaceuticals Inc - Asset Composition Analysis
Enanta Pharmaceuticals Inc Total Assets Breakdown (September 2025)
Enanta Pharmaceuticals Inc total assets breakdown as of September 2025. Enanta Pharmaceuticals Inc's total assets of $296.87 Million consist of 72.8% current assets and 27.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.5% |
| Accounts Receivable | $6.88 Million | 2.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Enanta Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of Enanta Pharmaceuticals Inc to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Enanta Pharmaceuticals Inc's current assets represent 72.8% of total assets in 2025, a decrease from 96.2% in 2011.
- Cash Position: Cash and equivalents constituted 11.5% of total assets in 2025, down from 26.2% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 2.5% of total assets.
Enanta Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Enanta Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Enanta Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.76 | 5.00 | 8.82 |
| Quick Ratio | 3.76 | 5.00 | 8.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $149.45 Million | $178.16 Million | $282.85 Million |
Enanta Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Enanta Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.89 |
| Latest Market Cap to Assets Ratio | 1.10 |
| Asset Growth Rate (YoY) | -25.5% |
| Total Assets | $280.73 Million |
| Market Capitalization | $310.19 Million USD |
Valuation Analysis
Above Book Valuation: The market values Enanta Pharmaceuticals Inc's assets above their book value (1.10x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Enanta Pharmaceuticals Inc's assets decreased by 25.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Enanta Pharmaceuticals Inc (2011–2025)
The table below shows the annual total assets of Enanta Pharmaceuticals Inc from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-09-30 | $280.73 Million | -25.47% |
| 2024-09-30 | $376.65 Million | -18.52% |
| 2023-09-30 | $462.27 Million | +21.46% |
| 2022-09-30 | $380.59 Million | -13.67% |
| 2021-09-30 | $440.86 Million | -10.17% |
| 2020-09-30 | $490.79 Million | +0.20% |
| 2019-09-30 | $489.83 Million | +18.25% |
| 2018-09-30 | $414.23 Million | +26.82% |
| 2017-09-30 | $326.64 Million | +16.13% |
| 2016-09-30 | $281.28 Million | +14.33% |
| 2015-09-30 | $246.01 Million | +58.29% |
| 2014-09-30 | $155.41 Million | +32.86% |
| 2013-09-30 | $116.97 Million | +124.25% |
| 2012-09-30 | $52.16 Million | +99.89% |
| 2011-09-30 | $26.10 Million | -- |
About Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respirato… Read more